Abstract
Will the future of antibacterial therapy rely on an ongoing pipeline of new small molecule, direct-acting antibacterial agents that inhibit or kill bacterial pathogens, referred to here as antibiotics? What role will these small-molecule antibiotics have in the control of the bacterial infections of the future? Although there is today increased activity in the field of new antibiotic discovery, the history of this field over the past 30 years is a history of low output. This low output of new antibiotics does not encourage confidence that they can be central to the future control of bacterial infection. This low productivity is often blamed upon financial disincentives in the pharmaceutical industry, and on regulatory difficulties. But I believe that a critical underlying reason for the dearth of novel products is the fundamental difficulty of the science, coupled with a failure to directly grapple with the key scientific challenges that prevent forward motion. The future fate of antibiotic discovery will depend upon the degree to which the rate limiting steps of discovery are fully recognized, and the discovery technology turns to overcoming these blockades.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Outterson K, Rex JH, Jinks T, Jackson P, Hallinan J, Karp S, Hung DT, Franceschi F, Merkeley T, Houchens C, Dixon DM, Kurilla MG, Aurigemma R, Larsen J (2016) Accelerating global innovation to address antibacterial resistance: introducing CARB-X. Nat Rev Drug Discov 15:589–590. doi:10.1038/nrd.2016.155
Hwang TJ, Carpenter D, Kesselheim AS (2014) Target small firms for antibiotic innovation. Science 344:967–969. doi:10.1126/science.1251419
Balasegaram M, Clift C, Røttingen JA (2015) The global innovation model for antibiotics needs reinvention. J Law Med Ethics 43(Suppl 3):22–26. doi:10.1111/jlme.12270
Livermore DM (2011) Discovery research: the scientific challenge of finding new antibiotics. J Antimicrob Chemother 66:1941–1944. doi:10.1093/jac/dkr262
Lange RP, Locher HH, Wyss PC, Then RL (2007) The targets of currently used antibacterial agents: lessons for drug discovery. Curr Pharm Des 13:3140–3154. doi:10.2174/138161207782110408
Overbye KM, Barrett JF (2005) Antibiotics: where did we go wrong? Drug Discov Today 10:45–52. doi:10.1016/S1359-6446(04)03285-4
Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL (2007) Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 6:29–40. doi:10.1038/nrd2201
Chan PF, Holmes DJ, Payne DJ (2004) Finding the gems using genomic discovery: antibacterial drug discovery strategies – the successes and the challenges. Drug Discov Today: Ther Strateg 1:519–527. doi:10.1016/j.ddstr.2004.11.003
Silver LL (2011) Challenges of antibacterial discovery. Clin Microbiol Rev 24:71–109. doi:10.1128/CMR.00030-10
Gwynn MN, Portnoy A, Rittenhouse SF, Payne DJ (2010) Challenges of antibacterial discovery revisited. Ann N Y Acad Sci 1213:5–19. doi:10.1111/j.1749-6632.2010.05828.x
Cegelski L, Marshall GR, Eldridge GR, Hultgren SJ (2008) The biology and future prospects of antivirulence therapies. Nat Rev Microbiol 6:17–27. doi:10.1038/nrmicro1818
Escaich S (2008) Antivirulence as a new antibacterial approach for chemotherapy. Curr Opin Chem Biol 12:400–408. doi:10.1016/j.cbpa.2008.06.022
Ruer S, Pinotsis N, Steadman D, et al. (2015) Virulence-targeted antibacterials: concept, promise, and susceptibility to resistance mechanisms. Chem Biol Drug Des 86:379–399. doi:10.1111/cbdd.12517
Dickey SW, Cheung GYC, Otto M (2017) Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance. Nat Rev Drug Discov. doi:10.1038/nrd.2017.23
Johnson BK, Abramovitch RB (2017) Small molecules that sabotage bacterial virulence. Trends Pharmacol Sci 38:339–362. doi:10.1016/j.tips.2017.01.004
Czaplewski L, Bax R, Clokie M, et al. (2016) Alternatives to antibiotics – a pipeline portfolio review. Lancet Infect Dis 16:239–251. doi:10.1016/s1473-3099(15)00466-1
Lévy FM (1975) The fiftieth anniversary of diphtheria and tetanus immunization. Prev Med 4(2):226–237. doi:10.1016/0091-7435(75)90084-5
Krishnamurthy M, Moore RT, Rajamani S, et al. (2016) Bacterial genome engineering and synthetic biology: combating pathogens. BMC Microbiol 16:258. doi:10.1186/s12866-016-0876-3
Silver LL (2014) Antibacterials for any target. Nat Biotechnol 32:1102–1104. doi:10.1038/nbt.3060
Bikard D, Euler C, Jiang W, et al. (2014) Development of sequence-specific antimicrobials based on programmable CRISPR-Cas nucleases. Nat Biotechnol 32:1146–1150. doi:10.1038/nbt.3043
Citorik R, Mimee M, Lu T (2014) Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases. Nat Biotechnol 32:1141–1145. doi:10.1038/nbt.3011
LocusBiosciences (2016) Founded by pioneers in the CRISPR field: engineering a novel class of precision medicines. http://www.locus-bio.com/. Accessed 1 Apr 2017
Silver LL (2007) Multi-targeting by monotherapeutic antibacterials. Nat Rev Drug Discov 6:41–55. doi:10.1038/nrd2022
Silver LL, Bostian KA (1993) Discovery and development of new antibiotics: the problem of antibiotic resistance. Antimicrob Agents Chemother 37:377–383. doi:10.1128/AAC.37.3.377
Brotz-Oesterhelt H, Brunner NA (2008) How many modes of action should an antibiotic have? Curr Opin Pharmacol 8:564–573. doi:10.1038/nrmicro2133
O’Dwyer K, Spivak A, Ingraham K, et al. (2015) Bacterial resistance to leucyl-tRNA synthetase inhibitor GSK2251052 develops during treatment of complicated urinary tract infections. Antimicrob Agents Chemother 59:289–298. doi:10.1128/AAC.03774-14
Twynholm M, Dalessandro M, Barker K et al (2013) Termination of Phase II program due to emergence of resistance (EOR) on-therapy. Paper presented at the 53rd interscience congress on antimicrobial agents and chemotherapy, Denver
VanScoy BD, Bulik CC, Moseley C et al (2013) Hollow fiber infection model mimics both the time-to-resistance emergence and magnitude of E. coli resistance to GSK052 occurring in a Phase 2b clinical study. In: 53rd interscience congress on antimicrobial agents and chemotherapy, Denver
Sutterlin HA, Malinverni JC, Lee SH et al. (2017) Antibacterial new target discovery: sentinel examples, strategies, and surveying success. In: Topics in medicinal chemistry. Springer, Heidelberg, pp 1–29. doi:10.1007/7355_2016_31
O’Neill AJ, Chopra I (2004) Preclinical evaluation of novel antibacterial agents by microbiological and molecular techniques. Expert Opin Investig Drugs 13:1045–1063. doi:10.1517/13543784.13.8.1045
Couce A, Blázquez J (2011) Estimating mutation rates in low-replication experiments. Mutat Res 714:26–32. doi:10.1016/j.mrfmmm.2011.06.005
Rosche WA, Foster PL (2000) Determining mutation rates in bacterial populations. Methods 20:4–17. doi:10.1006/meth.1999.0901
Young K (2006) In vitro antibacterial resistance selection and quantitation. Curr Protoc Pharmacol 34:13A.16.11–13A.16.22. doi:10.1002/0471141755.ph13a06s34
Hall BM, Ma C-X, Liang P, et al. (2009) Fluctuation AnaLysis CalculatOR: a web tool for the determination of mutation rate using Luria–Delbrück fluctuation analysis. Bioinformatics 25:1564–1565. doi:10.1093/bioinformatics/btp253
Luria SE, Delbrück M (1943) Mutations of bacteria from virus sensitivity to virus resistance. Genetics 28:491–511. doi:10.3410/f.3620966.3337067
O’Neill AJ, Chopra I, Martinez JL, et al. (2001) Use of mutator strains for characterization of novel antimicrobial agents. Antimicrob Agents Chemother 45:1599–1600. doi:10.1128/aac.45.1.1599-1600.2001
Miller K, O’Neill AJ, Chopra I (2004) Escherichia coli Mutators present an enhanced risk for emergence of antibiotic resistance during urinary tract infections. Antimicrob Agents Chemother 48:23–29. doi:10.1128/aac.48.1.23-29.2004
Hall LMC, Henderson-Begg SK (2006) Hypermutable bacteria isolated from humans – a critical analysis. Microbiology 152:2505–2514. doi:10.1099/mic.0.29079-0
Oliver A (2010) Mutators in cystic fibrosis chronic lung infection: prevalence, mechanisms, and consequences for antimicrobial therapy. Int J Med Microbiol 300:563–572. doi:10.1016/j.ijmm.2010.08.009
Komp Lindgren P, Higgins PG, Seifert H, et al. (2016) Prevalence of hypermutators among clinical Acinetobacter baumannii isolates. J Antimicrob Chemother 71:661–665. doi:10.1093/jac/dkv378
Andersson DI, Hughes D (2009) Gene amplification and adaptive evolution in bacteria. Annu Rev Genet 43:167–195. doi:10.1146/annurev-genet-102108-134805
Andersson DI, Hughes D (2014) Microbiological effects of sublethal levels of antibiotics. Nat Rev Microbiol 12:465–478. doi:10.1038/nrmicro3270
Hughes D, Andersson DI (2012) Selection of resistance at lethal and non-lethal antibiotic concentrations. Curr Opin Microbiol 15:555–560. doi:10.1016/j.mib.2012.07.005
Martinez J, Baquero F, Andersson D (2011) Beyond serial passages: new methods for predicting the emergence of resistance to novel antibiotics. Curr Opin Pharmacol 11:439–445. doi:10.1016/j.coph.2011.07.005
Tam VH, Schilling AN, Neshat S, et al. (2005) Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa. Antimicrob Agents Chemother 49:4920–4927. doi:10.1128/AAC.49.12.4920-4927.2005
Drusano GL (2003) Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin Infect Dis 36(Supp 1):S42–S50. doi:10.1086/344653
Gumbo T, Louie A, Deziel MR, et al. (2005) Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance. Antimicrob Agents Chemother 49:3178–3181. doi:10.1128/aac.49.8.3178-3181.2005
VanScoy B, McCauley J, Bhavnani SM, et al. (2016) Relationship between fosfomycin exposure and amplification of Escherichia coli subpopulations with reduced susceptibility in a hollow-fiber infection model. Antimicrob Agents Chemother 60:5141–5145. doi:10.1128/AAC.00355-16
Silver LL (2017) Fosfomycin: mechanism and resistance. Cold Spring Harb Perspect Med 7:a025262. doi:10.1101/cshperspect.a025262
Rodríguez-Rojas A, Maciá MD, Couce A, et al. (2010) Assessing the emergence of resistance: the absence of biological cost in vivo may compromise fosfomycin treatments for P. aeruginosa infections. PLoS One 5:e10193. doi:10.1371/journal.pone.0010193
VanScoy BD, McCauley J, Ellis-Grosse EJ, et al. (2015) Exploration of the pharmacokinetic-pharmacodynamic relationships for fosfomycin efficacy using an in vitro infection model. Antimicrob Agents Chemother 59:7170–7177. doi:10.1128/AAC.04955-14
Castañeda-García A, Blázquez J, Rodríguez-Rojas A (2013) Molecular mechanisms and clinical impact of acquired and intrinsic fosfomycin resistance. Antibiotics 2:217–236. doi:10.3390/antibiotics2020217
Endimiani A, Patel G, Hujer KM, et al. (2010) In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin. Antimicrob Agents Chemother 54:526–529. doi:10.1128/AAC.01235-09
Falagas ME, Giannopoulou KP, Kokolakis GN, et al. (2008) Fosfomycin: use beyond urinary tract and gastrointestinal infections. Clin Infect Dis 46:1069–1077. doi:10.1086/527442
Nilsson AI, Berg OG, Aspevall O, et al. (2003) Biological costs and mechanisms of fosfomycin resistance in Escherichia coli. Antimicrob Agents Chemother 47(9):2850–2858. doi:10.1128/aac.47.9.2850-2858.2003
Dong Y, Zhao X, Domagala J, et al. (1999) Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus. Antimicrob Agents Chemother 43:1756–1758
Leeds JA, Sachdeva M, Mullin S, et al. (2014) In vitro selection, via serial passage, of Clostridium difficile mutants with reduced susceptibility to fidaxomicin or vancomycin. J Antimicrob Chemother 69:41–44. doi:10.1093/jac/dkt302
Locher HH, Caspers P, Bruyere T, et al. (2014) Investigations of the mode of action and resistance development of cadazolid, a new antibiotic for treatment of Clostridium difficile infections. Antimicrob Agents Chemother 58:901–908. doi:10.1128/AAC.01831-13
Scott L (2013) Fidaxomicin: a review of its use in patients with Clostridium difficile infection. Drugs 73(15):1733–1747. doi:10.1007/s40265-013-0134-z
Zhao X, Drlica K (2008) A unified anti-mutant dosing strategy. J Antimicrob Chemother 62:434–436. doi:10.1093/jac/dkn229
Martinez MN, Papich MG, Drusano GL (2012) Dosing regimen matters: the importance of early intervention and rapid attainment of the pharmacokinetic/pharmacodynamic target. Antimicrob Agents Chemother 56:2795–2805. doi:10.1128/AAC.05360-11
Blondeau JM, Tillotson GS (2005) Antibiotic dosing: do we dose to cure the individual or do we treat the greater societal needs? Therapy 2:511–517. doi:10.1586/14750708.2.4.511
Drusano GL, Louie A, MacGowan A, et al. (2015) Suppression of emergence of resistance in pathogenic bacteria: keeping our powder dry, part 1. Antimicrob Agents Chemother 60:1183–1193. doi:10.1128/AAC.02177-15
Srinivas N, Jetter P, Ueberbacher BJ, et al. (2010) Peptidomimetic antibiotics target outer-membrane biogenesis in Pseudomonas aeruginosa. Science 327:1010–1013. doi:10.1126/science.1182749
Zeng D, Zhao J, Chung HS, et al. (2013) Mutants resistant to LpxC inhibitors by rebalancing cellular homeostasis. J Biol Chem 288:5475–5486. doi:10.1074/jbc.M112.447607
Erwin AL (2016) Antibacterial drug discovery targeting the lipopolysaccharide biosynthetic enzyme LpxC. Cold Spring Harb Perspect Med 6:a025304. doi:10.1101/cshperspect.a025304
Tomaras AP, McPherson CJ, Kuhn M, et al. (2014) LpxC inhibitors as new antibacterial agents and tools for studying regulation of lipid a biosynthesis in gram-negative pathogens. MBio 5:e01551–e01514. doi:10.1128/mBio.01551-14
Achaogen (2017) Achaogen is pursuing an advanced series of LpxC inhibitor compounds that are active against Pseudomonas aeruginosa. http://www.achaogen.com/lpxc-inhibitor-program/. Accessed 14 Apr 2017
Karlowsky JA, Kaplan N, Hafkin B, et al. (2009) AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-Specific Spectrum of activity. Antimicrob Agents Chemother 53:3544–3548. doi:10.1128/aac.00400-09
Yao J, Rock CO (2016) Resistance mechanisms and the future of bacterial enoyl-acyl carrier protein reductase (FabI)antibiotics. Cold Spring Harb Perspect Med 6:a027045. doi:10.1101/cshperspect.a027045
Yao J, Maxwell JB, Rock CO (2013) Resistance to AFN-1252 arises from missense mutations in Staphylococcus aureus enoyl-acyl carrier protein reductase (FabI). J Biol Chem 288:36261–36271. doi:10.1074/jbc.M113.512905
Moore RD, Chaisson RE (1999) Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS 13:1933–1942
Pirrone V, Thakkar N, Jacobson JM, et al. (2011) Combinatorial approaches to the prevention and treatment of HIV-1 infection. Antimicrob Agents Chemother 55:1831–1842. doi:10.1128/AAC.00976-10
Larder B, Darby G, Richman D (1989) HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243:1731–1734. doi:10.1126/science.2467383
Larder B, Kemp S, Harrigan P (1995) Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269:696–699. doi:10.1126/science.7542804
Ho DD, Bieniasz PD (2008) HIV-1 at 25. Cell 133(4):561–565. doi:10.1016/j.cell.2008.05.00
Aghemo A, De Francesco R (2013) New horizons in hepatitis C antiviral therapy with direct-acting antivirals. Hepatology 58:428–438. doi:10.1002/hep.26371
Lange CM, Jacobson IM, Rice CM, et al. (2014) Emerging therapies for the treatment of hepatitis C. EMBO Mol Med 6:4–15. doi:10.1002/emmm.201303131
Kwong AD (2014) The HCV revolution did not happen overnight. ACS Med Chem Lett 5:214–220. doi:10.1021/ml500070q
Shahid I, Almalki WH, Hafeez MH, et al. (2016) Hepatitis C virus infection treatment: an era of game changer direct acting antivirals and novel treatment strategies. Crit Rev Microbiol 42:535–547. doi:10.3109/1040841x.2014.970123
Kerantzas CA, Jacobs Jr WR (2017) Origins of combination therapy for tuberculosis: lessons for future antimicrobial development and application. MBio 8:e01586–e01516. doi:10.1128/mBio.01586-16
Arathoon EG, Hamilton JR, Hench CE, et al. (1990) Efficacy of short courses of oral novobiocin-rifampin in eradicating carrier state of methicillin-resistant Staphylococcus aureus and in vitro killing studies of clinical isolates. Antimicrob Agents Chemother 34:1655–1659. doi:10.1128/AAC.34.9.1655
Walsh TJ, Standiford HC, Reboli AC, et al. (1993) Randomized double-blinded trial of rifampin with either novobiocin or trimethoprim-sulfamethoxazole against methicillin-resistant Staphylococcus aureus colonization: prevention of antimicrobial resistance and effect of host factors on outcome. Antimicrob Agents Chemother 37:1334–1342. doi:10.1128/AAC.37.6.1334
Howden BP, Grayson ML (2006) Dumb and dumber – the potential waste of a useful antistaphylococcal agent: emerging fusidic acid resistance in Staphylococcus aureus. Clin Infect Dis 42:394–400. doi:10.1086/499365
Mandell GL, Moorman DR (1980) Treatment of experimental staphylococcal infections: effect of rifampin alone and in combination on development of rifampin resistance. Antimicrob Agents Chemother 17:658–662. doi:10.1128/aac.17.4.658
Huovinen P (2001) Resistance to trimethoprim-sulfamethoxazole. Clin Infect Dis 32:1608–1614. doi:10.1086/320532
Randall CP, Rasina D, Jirgensons A, et al. (2016) Targeting multiple aminoacyl-tRNA synthetases overcomes the resistance liabilities associated with antibacterial inhibitors acting on a single such enzyme. Antimicrob Agents Chemother 60:6359–6361. doi:10.1128/AAC.00674-16
Hurdle JG, O’Neill AJ, Ingham E, et al. (2004) Analysis of mupirocin resistance and fitness in Staphylococcus aureus by molecular genetic and structural modeling techniques. Antimicrob Agents Chemother 48:4366–4376. doi:10.1128/AAC.48.11.4366-4376.2004
Ochsner UA, Jarvis TC (2013) Aminoacyl-tRNA synthetase inhibitors. In: Gualerzi C, Brandi L, Fabbretti A, Pon C (eds) Antibiotics: targets, mechanisms and resistance. Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, pp 387–410. doi:10.1002/9783527659685.ch16
Drusano GL, Neely M, Van Guilder M, et al. (2014) Analysis of combination drug therapy to develop regimens with shortened duration of treatment for tuberculosis. PLoS One 9:e101311. doi:10.1371/journal.pone.0101311
Srivastava S, Sherman C, Meek C, et al. (2011) Pharmacokinetic mismatch does not lead to emergence of isoniazid or rifampin-resistant Mycobacterium tuberculosis, but better antimicrobial effect: a new paradigm for anti-tuberculosis drug scheduling. Antimicrob Agents Chemother 55:5085–5089. doi:10.1128/AAC.00269-11
Pasipanodya JG, Gumbo T (2011) A new evolutionary and pharmacokinetic-pharmacodynamic scenario for rapid emergence of resistance to single and multiple anti-tuberculosis drugs. Curr Opin Pharmacol 11:457–463. doi:10.1016/j.coph.2011.07.001
Drusano GL, Hope W, MacGowan A, et al. (2015) Suppression of emergence of resistance in pathogenic bacteria: keeping our powder dry, part 2. Antimicrob Agents Chemother 60:1194–1201. doi:10.1128/AAC.02231-15
Hameed PS, Manjrekar P, Chinnapattu M, et al. (2014) Pyrazolopyrimidines establish MurC as a vulnerable target in Pseudomonas aeruginosa and Escherichia coli. ACS Chem Biol 9:2274–2282. doi:10.1021/cb500360c
Mistry A, Warren MS, Cusick JK, et al. (2013) High-level pacidamycin resistance in Pseudomonas aeruginosa is mediated by an Opp oligopeptide permease encoded by the opp-fabI operon. Antimicrob Agents Chemother 57:5565–5571. doi:10.1128/aac.01198-13
Mann PA, Muller A, Xiao L, et al. (2013) Murgocil is a highly bioactive staphylococcal-specific inhibitor of the peptidoglycan glycosyltransferase enzyme MurG. ACS Chem Biol 8:2442–2451. doi:10.1021/cb400487f
Barbour AG, Mayer LW, Spratt BG (1981) Mecillinam resistance in Escherichia coli: dissociation of growth inhibition and morphologic change. J Infect Dis 143:114–121. doi:10.1093/infdis/143.1.114
Sakamoto Y, Furukawa S, Ogihara H, et al. (2003) Fosmidomycin resistance in adenylate cyclase deficient (cya) mutants of Escherichia coli. Biosci Biotechnol Biochem 67(9):2030–2033. doi:10.1271/bbb.67.2030
Wang H, Gill CJ, Lee SH, et al. (2013) Discovery of wall teichoic acid inhibitors as potential anti-MRSA β-lactam combination agents. Chem Biol 20:272–284. doi:10.1016/j.chembiol.2012.11.013
Haydon DJ, Stokes NR, Ure R, et al. (2008) An inhibitor of FtsZ with potent and selective anti-staphylococcal activity. Science 321:1673–1675. doi:10.1126/science.1159961
Kaul M, Mark L, Zhang Y, et al. (2015) TXA709, an FtsZ-targeting benzamide prodrug with improved pharmacokinetics and enhanced in vivo efficacy against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 59:4845–4855. doi:10.1128/AAC.00708-15
Robertson GT, Doyle TB, Du Q, et al. (2007) A novel indole compound that inhibits Pseudomonas aeruginosa growth by targeting MreB is a substrate for MexAB-OprM. J Bacteriol 189:6870–6881. doi:10.1128/jb.00805-07
McLeod SM, Fleming PR, MacCormack K, et al. (2015) Small-molecule inhibitors of gram-negative lipoprotein trafficking discovered by phenotypic screening. J Bacteriol 197:1075–1082. doi:10.1128/JB.02352-14
Inukai M, Takeuchi M, Shimizu K (1984) Effects of globomycin on the morphology of bacteria and the isolation of resistant mutants. Agric Biol Chem 48(2):513–518. doi:10.1271/bbb1961.48.513
Kaplan N, Albert M, Awrey D, et al. (2012) Mode of action, in vitro activity, and in vivo efficacy of AFN-1252, a selective antistaphylococcal FabI inhibitor. Antimicrob Agents Chemother 56:5865–5874. doi:10.1128/AAC.01411-12
de Jonge BL, Walkup GK, Lahiri SD, et al. (2013) Discovery of inhibitors of 4′-phosphopantetheine adenylyltransferase (PPAT) to validate PPAT as a target for antibacterial therapy. Antimicrob Agents Chemother 57:6005–6015. doi:10.1128/AAC.01661-13
Freiberg C, Brunner NA, Schiffer G, et al. (2004) Identification and characterization of the first class of potent bacterial acetyl-CoA carboxylase inhibitors with antibacterial activity. J Biol Chem 279:26066–26073. doi:10.1074/jbc.M402989200
Freiberg C, Pohlmann J, Nell PG, et al. (2006) Novel bacterial acetyl coenzyme a carboxylase inhibitors with antibiotic efficacy in vivo. Antimicrob Agents Chemother 50:2707–2712. doi:10.1128/AAC.00012-06
Miller JR, Dunham S, Mochalkin I, et al. (2009) A class of selective antibacterials derived from a protein kinase inhibitor pharmacophore. Proc Natl Acad Sci U S A 106:1737–1742. doi:10.1073/pnas.0811275106
Vickers AA, Potter NJ, Fishwick CWG, et al. (2009) Analysis of mutational resistance to trimethoprim in Staphylococcus aureus by genetic and structural modelling techniques. J Antimicrob Chemother 63:1112–1117. doi:10.1093/jac/dkp090
Kawatkar SP, Keating TA, Olivier NB, et al. (2014) Antibacterial inhibitors of gram-positive thymidylate kinase: SAR and chiral preference of a new hydrophobic binding region. J Med Chem 57:4584–4597. doi:10.1021/jm500463c
Painter RE, Adam GC, Arocho M, et al. (2015) Elucidation of DnaE as the antibacterial target of the natural product, nargenicin. Chem Biol 22:1362–1373. doi:10.1016/j.chembiol.2015.08.015
Kuhl A, Svenstrup N, Ladel C, et al. (2005) Biological characterization of novel inhibitors of the gram-positive DNA polymerase IIIC enzyme. Antimicrob Agents Chemother 49:987–995. doi:10.1128/aac.49.3.987-995.2005
Mills SD, Eakin AE, Buurman ET, et al. (2011) Novel bacterial NAD+-dependent DNA ligase inhibitors with broad spectrum activity and antibacterial efficacy in vivo. Antimicrob Agents Chemother 55:1088–1096. doi:10.1128/aac.01181-10
O’Neill AJ, Cove JH, Chopra I (2001) Mutation frequencies for resistance to fusidic acid and rifampicin in Staphylococcus aureus. J Antimicrob Chemother 47:647–650. doi:10.1093/jac/47.5.647
Leeds JA, LaMarche MJ, Brewer JT, et al. (2011) In vitro and in vivo activities of novel, semisynthetic thiopeptide inhibitors of bacterial elongation factor Tu. Antimicrob Agents Chemother 55:5277–5283. doi:10.1128/aac.00582-11
Sulavik MC, Houseweart C, Cramer C, et al. (2001) Antibiotic susceptibility profiles of Escherichia coli strains lacking multidrug efflux pump genes. Antimicrob Agents Chemother 45:1126–1136. doi:10.1128/aac.45.4.1126-1136.2001
Pucci MJ, Bronson JJ, Barrett JF, et al. (2004) Antimicrobial evaluation of nocathiacins, a thiazole peptide class of antibiotics. Antimicrob Agents Chemother 48:3697–3701. doi:10.1128/aac.48.10.3697-3701.2004
Montgomery JI, Smith JF, Tomaras AP, et al. (2014) Discovery and characterization of a novel class of pyrazolopyrimidinedione tRNA synthesis inhibitors. J Antibiot 68:361–367. doi:10.1038/ja.2014.163
Ochsner UA, Young CL, Stone KC, et al. (2005) Mode of action and biochemical characterization of REP8839, a novel inhibitor of methionyl-tRNA synthetase. Antimicrob Agents Chemother 49:4253–4262. doi:10.1128/aac.49.10.4253-4262.2005
Min S, Ingraham K, Huang J, et al. (2015) Frequency of spontaneous resistance to peptide deformylase inhibitor GSK1322322 in Haemophilus influenzae, Staphylococcus aureus, Streptococcus pyogenes, and Streptococcus pneumoniae. Antimicrob Agents Chemother 59:4644–4652. doi:10.1128/AAC.00484-15
Conlon BP, Nakayasu ES, Fleck LE, et al. (2013) Activated ClpP kills persisters and eradicates a chronic biofilm infection. Nature 503:365–370. doi:10.1038/nature12790. http://www.nature.com/nature/journal/vaop/ncurrent/abs/nature12790.html#supplementary-information
Howe JA, Wang H, Fischmann TO, et al. (2015) Selective small-molecule inhibition of an RNA structural element. Nature 526:672–677
Matsushima A, Takakura S, Fujihara N, et al. (2010) High prevalence of mutators among Enterobacter cloacae nosocomial isolates and their association with antimicrobial resistance and repetitive detection. Clin Microbiol Infect 16:1488–1493. doi:10.1111/j.1469-0691.2010.03145.x
Projan SJ (2008) Whither antibacterial drug discovery? Drug Discov Today 13(7–8):279–280. doi:10.1016/j.drudis.2008.03.010
Chait R, Vetsigian K, Kishony R (2012) What counters antibiotic resistance in nature? Nat Chem Biol 8:2–5. doi:10.1038/nchembio.745
Baym M, Stone LK, Kishony R (2016) Multidrug evolutionary strategies to reverse antibiotic resistance. Science 351:aad3292. doi:10.1126/science.aad3292
Yeh PJ, Hegreness MJ, Aiden AP, et al. (2009) Drug interactions and the evolution of antibiotic resistance. Nat Rev Microbiol 7:460–466. doi:10.1038/nrmicro2133
Silver LL (2013) Viable screening targets related to the bacterial cell wall. Ann N Y Acad Sci 1277:29–53. doi:10.1111/nyas.12006
Bugg TDH, Braddick D, Dowson CG, et al. (2011) Bacterial cell wall assembly: still an attractive antibacterial target. Trends Biotechnol 29:167–173. doi:10.1016/j.tibtech.2010.12.006
Katz AH, Caufield CE (2003) Structure-based design approaches to cell wall biosynthesis inhibitors. Curr Pharm Des 9:857–866. doi:10.2174/1381612033455305
Schneider T, Sahl H-G (2010) An oldie but a goodie – cell wall biosynthesis as antibiotic target pathway. Int J Med Microbiol 300:161–169. doi:10.1016/j.ijmm.2009.10.005
Janardhanan J, Chang M, Mobashery S (2016) The oxadiazole antibacterials. Curr Opin Microbiol 33:13–17. doi:10.1016/j.mib.2016.05.009
Spink E, Ding D, Peng Z, et al. (2015) Structure-activity relationship for the oxadiazole class of antibiotics. J Med Chem 58:1380–1389. doi:10.1021/jm501661f
Tomasic T, Zidar N, Kovac A, et al. (2010) 5-Benzylidenethiazolidin-4-ones as multitarget inhibitors of bacterial Mur ligases. ChemMedChem 5:286–295. doi:10.1002/cmdc.200900449
Ling LL, Schneider T, Peoples AJ, et al. (2015) A new antibiotic kills pathogens without detectable resistance. Nature 517:455–459. doi:10.1038/nature14098
Homma T, Nuxoll A, Brown Gandt A, et al. (2016) Dual targeting of cell wall precursors by teixobactin leads to cell lysis. Antimicrob Agents Chemother 60:6510–6517. doi:10.1128/AAC.01050-16
Arenz S, Wilson DN (2016) Bacterial protein synthesis as a target for antibiotic inhibition. Cold Spring Harb Perspect Med 6:a025361. doi:10.1101/cshperspect.a025361
Eyal Z, Matzov D, Krupkin M, et al. (2016) A novel pleuromutilin antibacterial compound, its binding mode and selectivity mechanism. Sci Rep 6:39004. doi:10.1038/srep39004
The-Pew-Charitable-Trusts (2014) Antibiotics currently in clinical development. http://www.pewtrusts.org/en/multimedia/data-visualizations/2014/antibiotics-currently-in-clinical-development. Accessed 14 Apr 2017
Melinta (2017) ESKAPE pathogen program. http://melinta.com/pipeline/eskape-pathogen-program/. Accessed 14 Apr 2017
Appili (2017) Pipeline. http://www.appilitherapeutics.com/pipeline/. Accessed 14 Apr 2017
Tse-Dinh Y-C (2016) Targeting bacterial topoisomerases: how to counter mechanisms of resistance. Future Med Chem 8:1085–1100. doi:10.4155/fmc-2016-0042
Kern G, Palmer T, Ehmann DE, et al. (2015) Inhibition of Neisseria gonorrhoeae type II topoisomerases by the novel spiropyrimidinetrione AZD0914. J Biol Chem 290(34):20984–20994. doi:10.1074/jbc.M115.663534
Biedenbach DJ, Bouchillon SK, Hackel M, et al. (2016) In vitro activity of gepotidacin, a novel triazaacenaphthylene bacterial topoisomerase inhibitor, against a broad spectrum of bacterial pathogens. Antimicrob Agents Chemother 60:1918–1923. doi:10.1128/aac.02820-15
Barbachyn MR (2008) Recent advances in the discovery of hybrid antibacterial agents. Annu Rep Med Chem 43:281–290. doi:10.1016/S0065-7743(08)00017-1
Ma Z, Lynch AS (2016) Development of a dual-acting antibacterial agent (TNP-2092) for the treatment of persistent bacterial infections. J Med Chem 59:6645–6657. doi:10.1021/acs.jmedchem.6b00485
Missner A, Pohl P (2009) 110 years of the Meyer–Overton rule: predicting membrane permeability of gases and other small compounds. ChemPhysChem 10:1405–1414. doi:10.1002/cphc.200900270
Lipinski C, Lombardo F, Dominy B, et al. (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 23:3–25. doi:10.1016/S0169-409X(96)00423-1
Veber DF, Johnson SR, Cheng H-Y, et al. (2002) Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 45:2615–2623. doi:10.1021/jm020017n
Lipinski CA (2003) Physicochemical properties and the discovery of orally active drugs: technical and people issues. In: Hicks M, Kettner C (eds) Molecular informatics: confronting complexity. Beilstein-Institut, Bozen
Zhang MQ, Wilkinson B (2007) Drug discovery beyond the ‘rule-of-five’. Curr Opin Biotechnol 18:478–488. doi:10.1016/j.copbio.2007.10.005
McFarland JW, Berger CM, Froshauer SA, et al. (1997) Quantitative SAR among macrolide antibacterial agents: in vitro and in vivo potency against Pasteurella multocida. J Med Chem 40:1340–1346. doi:10.1021/jm960436i
Nikaido H, Thanassi DG (1993) Penetration of lipophilic agents with multiple protonation sites into bacterial cells: tetracyclines and fluoroquinolones as examples. Antimicrob Agents Chemother 37:1393–1399
Rezai T, Yu B, Millhauser GL, et al. (2006) Testing the conformational hypothesis of passive membrane permeability using synthetic cyclic peptide diastereomers. J Am Chem Soc 128:2510–2511. doi:10.1021/ja0563455
Li XZ, Ma D, Livermore DM, et al. (1994) Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: active efflux as a contributing factor to β-lactam resistance. Antimicrob Agents Chemother 38:1742–1752. doi:10.1128/aac.38.8.1742
Cai H, Rose K, Liang L-H, et al. (2009) Development of a LC/MS-based drug accumulation assay in Pseudomonas aeruginosa. Anal Biochem 385:321–325. doi:10.1016/j.ab.2008.10.041
Davis TD, Gerry CJ, Tan DS (2014) General platform for systematic quantitative evaluation of small-molecule permeability in bacteria. ACS Chem Biol 9:2535–2544. doi:10.1021/cb5003015
Carey PR, Heidari-Torkabadi H (2015) New techniques in antibiotic discovery and resistance: Raman spectroscopy. Ann N Y Acad Sci 1354:67–81. doi:10.1111/nyas.12847
Nikaido H, Vaara M (1985) Molecular basis of bacterial outer membrane permeability. Microbiol Rev 49:1–32
Nikaido H (2003) Molecular basis of bacterial outer membrane permeability revisited. Microbiol Mol Biol Rev 67:593–656. doi:10.1128/mmbr.67.4.593-656.2003
Zgurskaya HI, López CA, Gnanakaran S (2015) Permeability barrier of gram-negative cell envelopes and approaches to bypass it. ACS Infect Dis 1:512–522. doi:10.1021/acsinfecdis.5b00097
Silver LL (2016) A gestalt approach to gram-negative entry. Bioorg Med Chem 24:6379–6389. doi:10.1016/j.bmc.2016.06.044
Manchester JI, Buurman ET, Bisacchi GS, et al. (2012) Molecular determinants of AcrB-mediated bacterial efflux implications for drug discovery. J Med Chem 55:2532–2537. doi:10.1021/jm201275d
Nikaido H, Pagès J-M (2012) Broad specificity efflux pumps and their role in multidrug resistance of gram negative bacteria. FEMS Microbiol Rev 36:340–363. doi:10.1111/j.1574-6976.2011.00290.x
Tommasi R, Brown DG, Walkup GK, et al. (2015) ESKAPEing the labyrinth of antibacterial discovery. Nat Rev Drug Discov 14:529–542. doi:10.1038/nrd4572
Krishnamoorthy G, Wolloscheck D, Weeks JW, et al. (2016) Breaking the permeability barrier of Escherichia coli by controlled hyperporination of the outer membrane. Antimicrob Agents Chemother 60:7372–7381. doi:10.1128/AAC.01882-16
Scorciapino M, Acosta-Gutierrez S, Benkerrou D, et al. (2017) Rationalizing the permeation of polar antibiotics into gram-negative bacteria. J Phys Condens Matter 29:113001. doi:10.1088/1361-648X/aa543b
Graef F, Vukosavljevic B, Michel JP, et al. (2016) The bacterial cell envelope as delimiter of anti-infective bioavailability – an in vitro permeation model of the gram-negative bacterial inner membrane. J Control Release 243:214–224. doi:10.1016/j.jconrel.2016.10.018
Lewis K (2010) Challenges and opportunities in antibiotic discovery. In: Choffnes E, Relman DA, Mack A (eds) Antibiotic resistance: implications for global health and novel intervention strategies: workshop summary. National Academies Press, Washington, pp 233–256
Silver LL (2008) Are natural products still the best source for antibacterial discovery? The bacterial entry factor. Expert Opin Drug Discov 3:487–500. doi:10.1517/17460441.3.5.487
Lewis K (2013) Platforms for antibiotic discovery. Nat Rev Drug Discov 12(5):371–387. doi:10.1038/nrd3975
Cinquin B, Maigre L, Pinet E, et al. (2015) Microspectrometric insights on the uptake of antibiotics at the single bacterial cell level. Sci Rep 5:17968. doi:10.1038/srep17968
Tian H, Six DA, Krucker T, et al. (2017) Subcellular chemical imaging of antibiotics in single bacteria using C60-secondary ion mass spectrometry. Anal Chem 89:5050–5057. doi:10.1021/acs.analchem.7b00466
Richter MF, Drown BS, Riley AP, et al. (2017) Predictive compound accumulation rules yield a broad-spectrum antibiotic. Nature 545:299–304. doi:10.1038/nature22308
Pewtrusts (2016) A scientific roadmap for antibiotic discovery. http://www.pewtrusts.org/en/research-and-analysis/reports/2016/05/a-scientific-roadmap-for-antibiotic-discovery. Accessed 14 Apr 2017
Shore CK, Coukell A (2016) Roadmap for antibiotic discovery. Nat Microbiol 1:16083. doi:10.1038/nmicrobiol.2016.83
Kim A, Kutschke A, Ehmann DE, et al. (2015) Pharmacodynamic profiling of a siderophore-conjugated monocarbam in Pseudomonas aeruginosa: assessing the risk for resistance and attenuated efficacy. Antimicrob Agents Chemother 59:7743–7752. doi:10.1128/AAC.00831-15
Tomaras AP, Crandon JL, McPherson CJ, et al. (2013) Adaptation-based resistance to siderophore-conjugated antibacterial agents by Pseudomonas aeruginosa. Antimicrob Agents Chemother 57:4197–4207. doi:10.1128/AAC.00629-13
Ghosh M, Miller PA, Mollmann U, et al. (2017) Targeted antibiotic delivery: selective siderophore conjugation with daptomycin confers potent activity against multi-drug resistant Acinetobacter baumannii both in vitro and in vivo. J Med Chem 60:4577–4583. doi:10.1021/acs.jmedchem.7b00102
Ito A, Nishikawa T, Matsumoto S, et al. (2016) Siderophore cephalosporin cefiderocol utilizes ferric iron transporter systems for antibacterial activity against Pseudomonas aeruginosa. Antimicrob Agents Chemother 60:7396–7401. doi:10.1128/AAC.01405-16
Hancock REW (1984) Alterations in outer membrane permeability. Annu Rev Microbiol 38:237–264. doi:10.1146/annurev.mi.38.100184.001321
Epand RM, Epand RF (2009) Lipid domains in bacterial membranes and the action of antimicrobial agents. Biochim Biophys Acta 1788:289–294. doi:10.1016/j.bbamem.2008.08.023
Plesiat P, Nikaido H (1992) Outer membranes of gram-negative bacteria are permeable to steroid probes. Mol Microbiol 6:1323–1333. doi:10.1111/j.1365-2958.1992.tb00853.x
Miller JR, Ingolia TD (1989) Cloning and characterization of β-lactam biosynthetic genes. Mol Microbiol 3:689–695. doi:10.1111/j.1365-2958.1989.tb00217.x
Nakashima T, Takahashi Y, Omura S (2016) Search for new compounds from Kitasato microbial library by physicochemical screening. Biochem Pharmacol 134:42–55. doi:10.1016/j.bcp.2016.09.026
Genilloud O (2014) The re-emerging role of microbial natural products in antibiotic discovery. Antonie Van Leeuwenhoek 106:173–188. doi:10.1007/s10482-014-0204-6
Harvey AL, Edrada-Ebel R, Quinn RJ (2015) The re-emergence of natural products for drug discovery in the genomics era. Nat Rev Drug Discov 14:111–129. doi:10.1038/nrd4510
Gaudencio SP, Pereira F (2015) Dereplication: racing to speed up the natural products discovery process. Nat Prod Rep 32:779–810. doi:10.1039/c4np00134f
Silver LL (2015) Natural products as a source of drug leads to overcome drug resistance. Future Microbiol 10:1711–1718. doi:10.2217/fmb.15.67
Silver LL (2012) Rational approaches to antibacterial discovery: pre-genomic directed and phenotypic screening. In: Dougherty TJ, Pucci MJ (eds) Antibiotic discovery and development. Springer, New York, pp 33–75. doi:10.1007/978-1-4614-1400-1_2
Monciardini P, Iorio M, Maffioli S, et al. (2014) Discovering new bioactive molecules from microbial sources. J Microbial Biotechnol 7:209–220. doi:10.1111/1751-7915.12123
Abrahams Garth L, Kumar A, Savvi S, et al. (2012) Pathway-selective sensitization of Mycobacterium tuberculosis for target-based whole-cell screening. Chem Biol 19:844–854. doi:10.1016/j.chembiol.2012.05.020
Adamek M, Spohn M, Stegmann E, et al. (2017) Mining bacterial genomes for secondary metabolite gene clusters. Methods Mol Biol 1520:23–47. doi:10.1007/978-1-4939-6634-9_2
Lewis K (2016) New approaches to antimicrobial discovery. Biochem Pharmacol 134:87–98. doi:10.1016/j.bcp.2016.11.002
Olano C, Méndez C, Salas J (2014) Strategies for the design and discovery of novel antibiotics using genetic engineering and genome mining. In: Villa TG, Veiga-Crespo P (eds) Antimicrobial compounds. Springer, Berlin Heidelberg, pp 1–25. doi:10.1007/978-3-642-40444-3_1
Bachmann B, Lanen S, Baltz R (2014) Microbial genome mining for accelerated natural products discovery: is a renaissance in the making? J Ind Microbiol Biotechnol 41:175–184. doi:10.1007/s10295-013-1389-9
Müller R, Wink J (2013) Future potential for anti-infectives – how to exploit biodiversity and genomic potential. Int J Med Microbiol 304:3–13. doi:10.1016/j.ijmm.2013.09.004
Wohlleben W, Mast Y, Stegmann E, et al. (2016) Antibiotic drug discovery. Microb Biotechnol 9:541–548. doi:10.1111/1751-7915.12388
Wang J, Soisson SM, Young K, et al. (2006) Platensimycin is a selective FabF inhibitor with potent antibiotic properties. Nature 44:358–361. doi:10.1038/nature04784
Wang J, Kodali S, Lee SH, et al. (2007) Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties. Proc Natl Acad Sci U S A 104(18):7612–7616. doi:10.1073/pnas.0700746104
CARB-X. CARB-X injects up to $48 million to accelerate first powered by CARB-X portfolio of drug discovery and development projects to tackle antibiotic resistance. http://www.carb-x.org/press. Accessed 14 Apr 2017
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Silver, L.L. (2017). The Antibiotic Future. In: Fisher, J.F., Mobashery, S., Miller, M.J. (eds) Antibacterials. Topics in Medicinal Chemistry, vol 25. Springer, Cham. https://doi.org/10.1007/7355_2017_24
Download citation
DOI: https://doi.org/10.1007/7355_2017_24
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-68096-5
Online ISBN: 978-3-319-68097-2
eBook Packages: Chemistry and Materials ScienceChemistry and Material Science (R0)